The molecular aetiology of the serpinopathies

International Journal of Biochemistry and Cell Biology

Volumn 40, Issue 6-7, 2008, Pages 1273-1286

  Davies, Mark J ^a   Lomas, David A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

1 Antitrypsin; Conformational disease; Neuroserpin; Proteinase inhibitor; Serpin

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTITHROMBIN; COMPLEMENT COMPONENT C1S INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUTANT PROTEIN; NEUROSERPIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMER; SERINE PROTEINASE INHIBITOR;

AMINO ACID SUBSTITUTION; AUTOPHAGY; AUTOSOMAL DOMINANT DISORDER; CYTOPATHOLOGY; DEGRADATION; DEMENTIA; ENDOPLASMIC RETICULUM; ENZYME DEFICIENCY; FAMILIAL ENCEPHALOPATHY WITH NEUROSERPIN INCLUSION BODY; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MOLECULAR BIOLOGY; POLYMERIZATION; PROTEIN CONFORMATION; PROTEIN FOLDING; REVIEW; SERPINOPATHY; SIGNAL TRANSDUCTION;

ALPHA 1-ANTITRYPSIN DEFICIENCY; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; SERINE PROTEINASE INHIBITORS; SERPINS;

EID: 43049147575     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2007.12.017     Document Type: Review

References (106)

1. Belorgey D., Crowther D.C., Mahadeva R., and Lomas D.A. Mutant neuroserpin (S49P) that causes familial encephalopathy with neuroserpin inclusion bodies is a poor proteinase inhibitor and readily forms polymers in vitro. J. Biol. Chem. 277 (2002) 17367-17373
2. Belorgey D., Sharp L.K., Crowther D.C., Onda M., Johansson J., and Lomas D.A. Neuroserpin Portland (Ser52Arg) is trapped as an inactive intermediate that rapidly forms polymers: Implications for the epilepsy seen in the dementia FENIB. Eur. J. Biochem. 271 (2004) 3360-3367
3. Berg N.O., and Eriksson S. Liver disease in adults with alpha-1-antitrypsin deficiency. N. Engl. J. Med. 287 (1972) 1264-1267
4. Billingsley G.D., Walter M.A., Hammond G.L., and Cox D.W. Physical mapping of four serpin genes: Alpha 1-antitrypsin, alpha 1-antichymotrypsin, corticosteroid-binding globulin, and protein C inhibitor, within a 280-kb region on chromosome I4q32.1. Am. J. Hum. Genet. 52 (1993) 343-353
5. Blanco I., Fernandez E., and Bustillo E.F. Alpha-1-antitrypsin PI phenotypes S and Z in Europe: An analysis of the published surveys. Clin. Genet. 60 (2001) 31-41
6. Bradshaw C.B., Davis R.L., Shrimpton A.E., Holohan P.D., Rea C.B., Fieglin D., et al. Cognitive deficits associated with a recently reported familial neurodegenerative disease: Familial encephalopathy with neuroserpin inclusion bodies. Arch. Neurol. 58 (2001) 1429-1434
7. Brantly M., Nukiwa T., and Crystal R.G. Molecular basis of alpha-1-antitrypsin deficiency. Am. J. Med. 84 (1988) 13-31
8. Cabral C.M., Liu Y., Moremen K.W., and Sifers R.N. Organizational diversity among distinct glycoprotein endoplasmic reticulum-associated degradation programs. Mol. Biol. Cell 13 (2002) 2639-2650
9. Calzado M.A., Bacher S., and Schmitz M.L. NF-kappaB inhibitors for the treatment of inflammatory diseases and cancer. Curr. Med. Chem. 14 (2007) 367-376
10. Carrell R.W., and Lomas D.A. Alpha1-antitrypsin deficiency-A model for conformational diseases. N. Engl. J. Med. 346 (2002) 45-53
11. Carvalho P., Goder V., and Rapoport T.A. Distinct ubiquitin-ligase complexes define convergent pathways for the degradation of ER proteins. Cell 126 (2006) 361-373
12. Chiao P.J., Na R., Niu J., Sclabas G.M., Dong Q., and Curley S.A. Role of Rel/NF-kappaB transcription factors in apoptosis of human hepatocellular carcinoma cells. Cancer 95 (2002) 1696-1705
13. Chow M.K., Lomas D.A., and Bottomley S.P. Promiscuous beta-strand interactions and the conformational diseases. Curr. Med. Chem. 11 (2004) 491-499
14. Cude K., Wang Y., Choi H.J., Hsuan S.L., Zhang H., Wang C.Y., et al. Regulation of the G2-M cell cycle progression by the ERK5-NFkappaB signaling pathway. J. Cell Biol. 177 (2007) 253-264
15. Dafforn T.R., Mahadeva R., Elliott P.R., Sivasothy P., and Lomas D.A. A kinetic mechanism for the polymerization of alpha1-antitrypsin. J. Biol. Chem. 274 (1999) 9548-9555
16. Davis R.L., Holohan P.D., Shrimpton A.E., Tatum A.H., Daucher J., Collins G.H., et al. Familial encephalopathy with neuroserpin inclusion bodies. Am. J. Pathol. 155 (1999) 1901-1913
17. Davis R.L., Shrimpton A.E., Carrell R.W., Lomas D.A., Gerhard L., Baumann B., et al. Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet 359 (2002) 2242-2247
18. Davis R.L., Shrimpton A.E., Holohan P.D., Bradshaw C., Feiglin D., Collins G.H., et al. Familial dementia caused by polymerization of mutant neuroserpin. Nature 401 (1999) 376-379
19. Denic V., Quan E.M., and Weissman JSw. A luminal surveillance complex that selects misfolded glycoproteins for ER-associated degradation. Cell 126 (2006) 349-359
20. Donoso G., Herzog V., and Schmitz A. Misfolded BiP is degraded by a proteasome-independent endoplasmic-reticulum-associated degradation pathway. Biochem. J. 387 (2005) 897-903
21. Elliott P.R., Abrahams J.P., and Lomas D.A. Wild-type alpha 1-antitrypsin is in the canonical inhibitory conformation. J. Mol. Biol. 275 (1998) 419-425
22. Elliott P.R., Lomas D.A., Carrell R.W., and Abrahams J.P. Inhibitory conformation of the reactive loop of alpha 1-antitrypsin. Nat. Struct. Biol. 3 (1996) 676-681
23. Elliott P.R., Pei X.Y., Dafforn T.R., and Lomas D.A. Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci. 9 (2000) 1274-1281
24. Fu L., and Sztul E. Traffic-independent function of the Sar1p/COPII machinery in proteasomal sorting of the cystic fibrosis transmembrane conductance regulator. J. Cell Biol. 160 (2003) 157-163
25. Gill J.S., and Windebank A.J. Ceramide initiates NFkappaB-mediated caspase activation in neuronal apoptosis. Neurobiol. Dis. 7 (2000) 448-461
26. Gooptu B., Hazes B., Chang W.S., Dafforn T.R., Carrell R.W., Read R.J., et al. Inactive conformation of the serpin alpha(1)-antichymotrypsin indicates two-stage insertion of the reactive loop: Implications for inhibitory function and conformational disease. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 67-72
27. Graham B., and Gibson S.B. The two faces of NFkappaB in cell survival responses. Cell Cycle 4 (2005) 1342-1345
28. Green C., Brown G., Dafforn T.R., Reichhart J.M., Morley T., Lomas D.A., et al. Drosophila necrotic mutations mirror disease-associated variants of human serpins. Development 130 (2003) 1473-1478
29. Hidvegi T., Mirnics K., Hale P., Ewing M., Beckett C., and Perlmutter D.H. Regulator of G signaling 16 is a marker for the distinct ER stress state associated with aggregated mutant alpha 1antitrypsin Z in the classical form of alpha 1antitrypsin deficiency. J. Biol. Chem. (2007)
30. Hidvegi T., Schmidt B.Z., Hale P., and Perlmutter D.H. Accumulation of mutant alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and -12, NFkappaB, and BAP31 but not the unfolded protein response. J. Biol. Chem. 280 (2005) 39002-39015
31. Hitomi J., Katayama T., Eguchi Y., Kudo T., Taniguchi M., Koyama Y., et al. Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and A beta-induced cell death. J. Cell Biol. 165 (2004) 347-356
32. Huntington J.A., Read R.J., and Carrell R.W. Structure of a serpin-protease complex shows inhibition by deformation. Nature 407 (2000) 923-926
33. Inagi R., Nangaku M., Usuda N., Shimizu A., Onogi H., Izuhara Y., et al. Novel serpinopathy in rat kidney and pancreas induced by overexpression of megsin. J. Am. Soc. Nephrol. 16 (2005) 1339-1349
34. James E.L., and Bottomley S.P. The mechanism of alpha 1-antitrypsin polymerization probed by fluorescence spectroscopy. Arch. Biochem. Biophys. 356 (1998) 296-300
35. Janciauskiene S., Dominaitiene R., Sternby N.H., Piitulainen E., and Eriksson S. Detection of circulating and endothelial cell polymers of Z and wild type alpha 1-antitrypsin by a monoclonal antibody. J. Biol. Chem. 277 (2002) 26540-26546
36. Janciauskiene S., Eriksson S., Callea F., Mallya M., Zhou A., Seyama K., et al. Differential detection of PAS-positive inclusions formed by the Z, Siiyama, and Mmalton variants of alpha1-antitrypsin. Hepatology 40 (2004) 1203-1210
37. Jeppsson J.O., and Eriksson S. The N-terminal amino acid sequence from alpha 1-antitrypsin isolated from liver inclusion bodies. Biochim. Biophys. Acta 831 (1985) 30-33
38. Jin L., Abrahams J.P., Skinner R., Petitou M., Pike R.N., and Carrell R.W. The anticoagulant activation of antithrombin by heparin. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 14683-14688
39. Kamimoto T., Shoji S., Hidvegi T., Mizushima N., Umebayashi K., Perlmutter D.H., et al. Intracellular inclusions containing mutant alpha1-antitrypsin Z are propagated in the absence of autophagic activity. J. Biol. Chem. 281 (2006) 4467-4476
40. Kang H.A., Sohn J.H., Choi E.S., Chung B.H., Yu M.H., and Rhee S.K. Glycosylation of human alpha 1-antitrypsin in Saccharomyces cerevisiae and methylotrophic yeasts. Yeast 14 (1998) 371-381
41. Kim J., Lee K.N., Yi G.S., and Yu M.H. A thermostable mutation located at the hydrophobic core of alpha 1-antitrypsin suppresses the folding defect of the Z-type variant. J. Biol. Chem. 270 (1995) 8597-8601
42. Kim S., Woo J., Seo E.J., Yu M., and Ryu S. A 2.1 A resolution structure of an uncleaved alpha(1)-antitrypsin shows variability of the reactive center and other loops. J. Mol. Biol. 306 (2001) 109-119
43. Klionsky D.J., and Emr S.D. Autophagy as a regulated pathway of cellular degradation. Science 290 (2000) 1717-1721
44. Knorre A., Wagner M., Schaefer H.E., Colledge W.H., and Pahl H.L. DeltaF508-CFTR causes constitutive NF-kappaB activation through an ER-overload response in cystic fibrosis lungs. Biol. Chem. 383 (2002) 271-282
45. Kopito R.R. Biosynthesis and degradation of CFTR. Physiol. Rev. 79 (1999) S167-S173
46. Kruse K.B., Brodsky J.L., and McCracken A.A. Characterization of an ERAD gene as VPS30/ATG6 reveals two alternative and functionally distinct protein quality control pathways: One for soluble Z variant of human alpha-1 proteinase inhibitor (A1PiZ) and another for aggregates of A1PiZ. Mol. Biol. Cell 17 (2006) 203-212
47. Laskowski Jr. M., and Kato I. Protein inhibitors of proteinases. Annu. Rev. Biochem. 49 (1980) 593-626
48. Lawless M.W., Greene C.M., Mulgrew A., Taggart C.C., O'Neill S.J., and McElvaney N.G. Activation of endoplasmic reticulum-specific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency. J. Immunol. 172 (2004) 5722-5726
49. Li J., Wang Z., Canagarajah B., Jiang H., Kanost M., and Goldsmith E.J. The structure of active serpin 1 K from Manduca sexta. Structure 7 (1999) 103-109
50. Lin L., Schmidt B., Teckman J., and Perlmutter D.H. A naturally occurring nonpolymerogenic mutant of alpha 1-antitrypsin characterized by prolonged retention in the endoplasmic reticulum. J. Biol. Chem. 276 (2001) 33893-33898
51. Loebermann H., Tokuoka R., Deisenhofer J., and Huber R. Human alpha-1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J. Mol. Biol. 177 (1984) 531-557
52. Lomas D.A., Belorgey D., Mallya M., Miranda E., Kinghorn K.J., Sharp L.K., et al. Molecular mousetraps and the serpinopathies. Biochem. Soc. Trans. 33 (2005) 321-330
53. Lomas D.A., and Carrell R.W. Serpinopathies and the conformational dementias. Nat. Rev. Genet. 3 (2002) 759-768
54. Lomas D.A., Elliott P.R., Sidhar S.K., Foreman R.C., Finch J.T., Cox D.W., et al. Alpha 1-antitrypsin Mmalton (Phe52-deleted) forms loop-sheet polymers in vivo. Evidence for the C sheet mechanism of polymerisation. J. Biol. Chem. 270 (1995) 16864-16870
55. Lomas D.A., Evans D.L., Finch J.T., and Carrell R.W. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 357 (1992) 605-607
56. Lomas D.A., Finch J.T., Seyama K., Nukiwa T., and Carrell R.W. Alpha 1-antitrypsin Siiyama (Ser53-->Phe). Further evidence for intracellular loop-sheet polymerisation. J. Biol. Chem. 268 (1993) 15333-15335
57. Lomas D.A., and Mahadeva R. Alpha-1-antitrypsin polymerisation and the serpinopathies: Pathobiology and prospects for therapy. J. Clin. Invest. 110 (2002) 1585-1590
58. Mahadeva R., Chang W.S., Dafforn T.R., Oakley D.J., Foreman R.C., Calvin J., et al. Heteropolymerization of S, I, and Z alpha1-antitrypsin and liver cirrhosis. J Clin Invest 103 (1999) 999-1006
59. Mahadeva R., Dafforn T.R., Carrell R.W., and Lomas D.A. 6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerisation. Implications for the prevention of Z alpha(1)-antitrypsin-related cirrhosis. J. Biol. Chem. 277 (2002) 6771-6774
60. Mayer T.U., Braun T., and Jentsch S. Role of the proteasome in membrane extraction of a short-lived ER-transmembrane protein. EMBO J. 17 (1998) 3251-3257
61. McCracken A.A., and Brodsky J.L. Assembly of ER-associated protein degradation in vitro: Dependence on cytosol, calnexin, and ATP. J. Cell Biol. 132 (1996) 291-298
62. Miranda E., Romisch K., and Lomas D.A. Mutants of neuroserpin that cause dementia accumulate as polymers within the endoplasmic reticulum. J. Biol. Chem. 279 (2004) 28283-28291
63. Nadanaka S., Yoshida H., Kano F., Murata M., and Mori K. Activation of mammalian unfolded protein response is compatible with the quality control system operating in the endoplasmic reticulum. Mol. Biol. Cell 15 (2004) 2537-2548
64. Nakagawa T., Zhu H., Morishima N., Li E., and Xu J. Yankner BA, and Yuan J. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403 (2000) 98-103
65. Needham M., and Stockley R.A. Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history. Thorax 59 (2004) 441-445
66. Noda T., and Farquhar M.G. A non-autophagic pathway for diversion of ER secretory proteins to lysosomes. J. Cell Biol. 119 (1992) 85-97
67. Olivier S., Robe P., and Bours V. Can NF-kappaB be a target for novel and efficient anti-cancer agents?. Biochem. Pharmacol. 72 (2006) 1054-1068
68. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18 (1999) 6853-6866
69. Pahl H.L., and Baeuerle P.A. Activation of NF-kappa B by ER stress requires both Ca2+ and reactive oxygen intermediates as messengers. FEBS Lett. 392 (1996) 129-136
70. Pahl H.L., and Baeuerle P.A. A novel signal transduction pathway from the endoplasmic reticulum to the nucleus is mediated by transcription factor NF-kappa B. EMBO J 14 (1995) 2580-2588
71. Pahl H.L., Sester M., Burgert H.G., and Baeuerle P.A. Activation of transcription factor NF-kappaB by the adenovirus E3/19 K protein requires its ER retention. J. Cell Biol. 132 (1996) 511-522
72. Palmer E.A., Kruse K.B., Fewell S.W., Buchanan S.M., Brodsky J.L., and McCracken A.A. Differential requirements of novel A1PiZ degradation deficient (ADD) genes in ER-associated protein degradation. J. Cell Sci. 116 (2003) 2361-2373
73. Perlmutter D.H. Pathogenesis of chronic liver injury and hepatocellular carcinoma in alpha-1-antitrypsin deficiency. Pediatr. Res. 60 (2006) 233-238
74. Purkayastha P., Klemke J.W., Lavender S., Oyola R., Cooperman B.S., and Gai F. Alpha 1-antitrypsin polymerization: A fluorescence correlation spectroscopic study. Biochemistry 44 (2005) 2642-2649
75. Qu D., Teckman J.H., Omura S., and Perlmutter D.H. Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J. Biol. Chem. 271 (1996) 22791-22795
76. Roberts E.A., Cox D.W., Medline A., and Wanless I.R. Occurrence of alpha-1-antitrypsin deficiency in 155 patients with alcoholic liver disease. Am. J. Clin. Pathol. 82 (1984) 424-427
77. Romisch K. Endoplasmic reticulum-associated degradation. Annu. Rev. Cell Dev. Biol. 21 (2005) 435-456
78. Ron D., and Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8 (2007) 519-529
79. Rudnick D.A., Liao Y., An J.K., Muglia L.J., Perlmutter D.H., and Teckman J.H. Analyses of hepatocellular proliferation in a mouse model of alpha-1-antitrypsin deficiency. Hepatology 39 (2004) 1048-1055
80. Ryu S.E., Choi H.J., Kwon K.S., Lee K.N., and Yu M.H. The native strains in the hydrophobic core and flexible reactive loop of a serine protease inhibitor: Crystal structure of an uncleaved alpha1-antitrypsin at 2.7 A. Structure 4 (1996) 1181-1192
81. Schmidt B.Z., and Perlmutter D.H. Grp78, Grp94, and Grp170 interact with alpha1-antitrypsin mutants that are retained in the endoplasmic reticulum. Am. J. Physiol. Gastrointest. Liver Physiol. 289 (2005) G444-G455
82. Schroder M., and Kaufman R.J. The mammalian unfolded protein response. Annu. Rev. Biochem. 74 (2005) 739-789
83. Scott C.M., Kruse K.B., Schmidt B.Z., Perlmutter D.H., McCracken A.A., and Brodsky J.L. ADD66, a Gene Involved in the endoplasmic reticulum associated degradation (ERAD) of alpha-1-antitrypsin-Z in yeast, facilitates proteasome activity and assembly. Mol. Biol. Cell (2007)
84. Seyama K., Nukiwa T., Souma S., Shimizu K., and Kira S. Alpha 1-antitrypsin-deficient variant Siiyama (Ser53[TCC] to Phe53[TTC]) is prevalent in Japan. Status of alpha 1-antitrypsin deficiency in Japan. Am. J. Respir. Crit. Care Med. 152 (1995) 2119-2126
85. Seyama K., Nukiwa T., Takabe K., Takahashi H., Miyake K., and Kira S. Siiyama (serine 53 (TCC) to phenylalanine 53 (TTC)). A new alpha 1-antitrypsin-deficient variant with mutation on a predicted conserved residue of the serpin backbone. J. Biol. Chem. 266 (1991) 12627-12632
86. Sharp H.L., Bridges R.A., Krivit W., and Freier E.F. Cirrhosis associated with alpha-1-antitrypsin deficiency: A previously unrecognized inherited disorder. J. Lab. Clin. Med. 73 (1969) 934-939
87. Silverman G.A., Bird P.I., Carrell R.W., Church F.C., Coughlin P.B., Gettins P.G., et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 276 (2001) 33293-33296
88. Sivasothy P., Dafforn T.R., Gettins P.G., and Lomas D.A. Pathogenic alpha 1-antitrypsin polymers are formed by reactive loop-beta-sheet A linkage. J. Biol. Chem. 275 (2000) 33663-33668
89. Stratikos E., and Gettins P.G. Major proteinase movement upon stable serpin-proteinase complex formation. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 453-458
90. Stratikos E., and Gettins P.G. Mapping the serpin-proteinase complex using single cysteine variants of alpha1-proteinase inhibitor Pittsburgh. J. Biol. Chem. 273 (1998) 15582-15589
91. Teckman J.H., An J.K., Blomenkamp K., Schmidt B., and Perlmutter D. Mitochondrial autophagy and injury in the liver in alpha 1-antitrypsin deficiency. Am. J. Physiol. Gastrointest. Liver Physiol. 286 (2004) G851-G862
92. Teckman J.H., An J.K., Loethen S., and Perlmutter D.H. Fasting in alpha1-antitrypsin deficient liver: Constitutive [correction of consultative] activation of autophagy. Am. J. Physiol. Gastrointest. Liver Physiol. 283 (2002) G1156-G1165
93. Teckman J.H., Burrows J., Hidvegi T., Schmidt B., Hale P.D., and Perlmutter D.H. The proteasome participates in degradation of mutant alpha 1-antitrypsin Z in the endoplasmic reticulum of hepatoma-derived hepatocytes. J. Biol. Chem. 276 (2001) 44865-44872
94. Teckman J.H., Gilmore R., and Perlmutter D.H. Role of ubiquitin in proteasomal degradation of mutant alpha(1)-antitrypsin Z in the endoplasmic reticulum. Am. J. Physiol. Gastrointest. Liver Physiol. 278 (2000) G39-G48
95. Teckman J.H., and Perlmutter D.H. Retention of mutant alpha(1)-antitrypsin Z in endoplasmic reticulum is associated with an autophagic response. Am. J. Physiol. Gastrointest. Liver Physiol. 279 (2000) G961-G974
96. Tergaonkar V. NFkappaB pathway: A good signaling paradigm and therapeutic target. Int. J. Biochem. Cell Biol. 38 (2006) 1647-1653
97. Tirosh B., Furman M.H., Tortorella D., and Ploegh H.L. Protein unfolding is not a prerequisite for endoplasmic reticulum-to-cytosol dislocation. J. Biol. Chem. 278 (2003) 6664-6672
98. Travis J., and Salvesen G.S. Human plasma proteinase inhibitors. Annu. Rev. Biochem. 52 (1983) 655-709
99. Trombetta E.S., and Parodi A.J. Quality control and protein folding in the secretory pathway. Annu. Rev. Cell Dev. Biol. 19 (2003) 649-676
100. Werner E.D., Brodsky J.L., and McCracken A.A. Proteasome-dependent endoplasmic reticulum-associated protein degradation: An unconventional route to a familiar fate. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 13797-13801
101. Whitsett J.A., and Weaver T.E. Hydrophobic surfactant proteins in lung function and disease. N. Engl. J. Med. 347 (2002) 2141-2148
102. Wilczynska M., Fa M., Karolin J., Ohlsson P.I., Johansson L.B., and Ny T. Structural insights into serpin-protease complexes reveal the inhibitory mechanism of serpins. Nat. Struct. Biol. 4 (1997) 354-357
103. Wilczynska M., Fa M., Ohlsson P.I., and Ny T. The inhibition mechanism of serpins. Evidence that the mobile reactive center loop is cleaved in the native protease-inhibitor complex. J Biol. Chem. 270 (1995) 29652-29655
104. Wu Y., Swulius M.T., Moremen K.W., and Sifers R.N. Elucidation of the molecular logic by which misfolded alpha 1-antitrypsin is preferentially selected for degradation. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 8229-8234
105. Wu Y., Whitman I., Molmenti E., Moore K., Hippenmeyer P., and Perlmutter D.H. A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 9014-9018
106. Zhou A., Stein P.E., Huntington J.A., and Carrell R.W. Serpin polymerization is prevented by a hydrogen bond network that is centered on his-334 and stabilized by glycerol. J Biol. Chem. 278 (2003) 15116-15122